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ABSTRACT 
Evidence increasingly confirms that synthetic chemicals disrupt the endocrine system and 
contribute to disease and disability across the lifespan. Despite a United Nations Environment 
Programme/WHO report affirmed by over 100 countries at the Fourth International Conference 
on Chemicals Management, ‘manufactured doubt’ continues to be cast as a cloud over rigorous, 
peer- reviewed and independently funded scientific data. This study describes the sources of 
doubt and their social costs, and suggested courses of action by policymakers to prevent disease 
and disability. The problem is largely based on the available data, which are all too limited. 
Rigorous testing programmes should not simply focus on oestrogen, androgen and thyroid. 
Tests should have proper statistical power. ‘Good laboratory practice’ (GLP) hardly represents a 
proper or even gold standard for laboratory studies of endocrine disruption. Studies should be 
evaluated with regard to the contamination of negative controls, responsiveness to positive 
controls and dissection techniques. Flaws in many GLP studies have been identified, yet 
regulatory agencies rely on these flawed studies. Peer-reviewed and unbiased research, rather 
than ‘sound science’, should be used to evaluate endocrine-disrupting chemicals. 
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The state of the science on endocrine-disrupting chemicals 
Endocrine-disrupting chemicals (EDCs) are compounds or mixtures of compounds that interfere 
with hormone action and thereby contribute to disease and disability.1 In 1996, when the 
studies of EDCs were in their infancy, the US EPA defined endocrine disruptors as ‘exogenous 
agent[s] that interfere with the synthesis, secretion, transport, binding, action, or elimination of 
natural hormones in the body which are responsible for the maintenance of homeostasis, 
reproduction, development and/or behavior’.2 
The chemicals’ landscape has changed drastically in the past decades, with >85 000 chemicals 
on the market and thousands more that have been produced (figure 1). Simple compiling of 
programmes like those used in the US EPA’s Endocrine Disruptor Knowledge Base3 and 
evaluations of the published, peer-reviewed scientific literature by the international non-profit 
organisation, the Endocrine Disruptor Exchange4 have identified >1000 chemicals with 
potential endocrinedisrupting properties. The US Environmental Protection Agency’s (EPA) 
Endocrine Disruptor Knowledge Base identifies only those chemicals that bind to three hormone 
receptors: oestrogen, androgen and thyroid (n>1800).5 A more comprehensive examination of 
all hormones relevant to human physiology is likely to yield a much larger number than this 
limited EPA screening effort. In addition, EDCs can display actions beyond simple receptor 
binding, and so even a broad examination of hormone receptor binding would yield a vast 
underestimate of the total number of EDCs. 
In 2002, one of the first international reports on EDCs was written by experts and assembled by 
the International Programme on Chemical Safety and WHO.6 More recent reports and scientific 
statements from the Endocrine Society7 8 and the WHO and United Nations Environment 
Programme (UNEP) have reviewed studies demonstrating the relationship between EDC 
exposures and endocrine diseases in controlled animal studies and human populations.9 Other 
scientific organisations have followed these scientific statements with additional expressions of 
concern including the International Federation of Gynecologists and Obstetricians, which called 
for the reduction of prenatal EDC exposures to prevent a broad array of female reproductive and 
other problems across the life course.10 
Evidence reviewed in these scientific statements increasingly confirms that synthetic chemicals 
disrupt the endocrine system and contribute to disease and disability across the lifespan. 
Sufficient evidence demonstrates that EDCs can induce diseases and dysfunctions including 
neurodevelopmental and cognitive deficits, infertility and other reproductive disorders, obesity 
and diabetes, immune dysfunction, asthma and cancers.8 Epidemiological studies similarly 
suggest associations between EDC exposures and these conditions in environmentally exposed 
populations. For some compounds, the coherence between epidemiological studies at the doses 
encountered in current populations and in vivo experiments (and also sometimes in vitro 
studies) adds to the strength of arguments for causality. Examples include phthalates and their 
disruption of metabolic processes, as well as organophosphates and brominated flame 
retardants and disruption of prenatal thyroid with neurocognitive consequences.11 12 
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EDCs : how controversial are they ? 
After the publication of the 2012 UNEP/WHO report on EDCs, a number of critical statements 
were published in the scientific literature.13 14 These rebuttals of the UNEP/WHO report raised a 
number of issues including concerns that the report did not use systematic review criteria in the 
evaluation of evidence.15 Yet, these rebuttals included many scientifically inaccurate comments, 
specifically misrepresenting criteria for interpreting causation as originally elaborated by Sir 
Austin Bradford Hill some 50 years ago,16 incorrectly suggesting that standardised ‘weight of 
evidence’ approaches can be readily applied to evaluate endocrine disruption, and dismissing 
low-dose effects as well as nonlinear and non-monotonic exposure-response relationships that 
are extremely well documented. Concerns raised about the UNEP/WHO report were rebutted in 
a number of recent articles by the UNEP/WHO authors and others.17-19 A recent manuscript 
noted parallels between the rebuttals of the UNEP/WHO report and tactics once used by the 
tobacco industry to prevent public health actions and scientific progress.17 These approaches 
also include the failure of many authors to report conflicts of interest including paid 
consultancies for industries that manufacture EDCs.20 
The UNEP/WHO report was welcomed at the Fourth International Conference on Chemicals 
Management (ICCM4). More than 100 countries present at this conference agreed by consensus 
on four key points:21 (1) EDC exposures can result in adverse effects in humans and wildlife; (2) 
the most vulnerable period for EDC exposure is during embryogenesis, fetal development and 
perinatal life, when organ systems are developing; (3) EDC exposures during development can 
result in adult-onset diseases and (4) focus should be on reducing EDC exposures. Interestingly, 
there was one major exception to the acceptance of the UNEP/WHO report by the participants at 
ICCM4: industry associations representing global chemicals and pesticide producers and a US 
business association registered their disagreement with the state of science. A footnote in the 
ICCM4 report thus identifies the limited stakeholders who dispute the UNEP/WHO report, 
stating ‘The International Council of Chemical Associations, CropLife International and the 
United States Council for International Business wish to note that the methodology and 
conclusions of the report remain contentious amongst certain scientific groups’. 
Additional meetings and reports22-24 have demonstrated that much of the debate on the concerns 
over EDC exposures represents ‘manufactured doubt’.25 What does this mean about the 
controversial nature of EDCs? Clearly, there are still many aspects of endocrine disruptor science 
that are unsettled, but these are generally related to the mechanisms responsible for the action 
of EDCs, rather than the principal induction of health outcomes themselves. Further research is 
needed to understand the extent of adverse effects that can be induced by each possible EDC, the 
precise shapes of dose-response functions for all exposure-disease pairs and the exact public 
health impact. 
Similar ‘manufactured doubt’ existed about lead and its effects on the developing brain, despite 
substantial and accelerating evidence documenting adverse effects on young children that were 
permanent and lifelong. Policy action to remove lead from gasoline occurred even with 
incomplete information available. Scientific experts, then as now, provided data that 
policymakers interpreted and decided how to protect society while balancing other interests. 
While scientists are humans and are also affected by personal values, we aim for objectivity, 
Published in : Journal of Epidemiology & Community Health (2016), vol. 70, n°11, pp. 
1051-1056 
DOI: 10.1136/jech-2016-207841 




recognising a responsibility to communicate real and serious threats when they are present. The 
current scientific evidence for endocrine disruption parallels that which existed for climate 
change just a few years ago. As citizens, our responsibility is to communicate the reality that the 
scientific case for policy action is now strong, and the health of future generations is clearly at 
stake. 
Sound science : who could be against it ? 
Recent calls for ‘sound science’ in the evaluation of EDC data have been made by groups like the 
American Chemistry Council.26 In Doubt is their Product, David Michaels notes that the origin of 
the term ‘sound science’ can be traced back to the tobacco industry. Michaels wrote,27 ‘The 
vilification of any research that might threaten corporate interests as “junk science” and the 
sanctification of its own bought-and-paid-for research as “sound science” is indeed Orwellian—
and nothing less than standard operating procedure today. But to give credit where credit is due, 
the sound science/junk science dichotomy has worked wonders as a public relations gimmick 
and has gained widespread acceptance in the current debate over the use of scientific evidence 
as policy’. 
‘Sound science’ seems like something that all scientists should support. Who could be against 
good, transparent science? In the case of EDCs, the chemicals industry has suggested that ‘sound 
science’ requires the use of good laboratory practices (GLPs), a series of recordkeeping 
procedures and data-reporting protocols. GLP was actually instituted in response to serious 
cases of fraud after industry and contract laboratories were found to have falsified chemical 
toxicity data.28 Because of the regulatory and financial burden associated with GLP, studies that 
comply with these regulations are typically conducted by the industry or contract laboratories 
hired by the industry; academic laboratories are rarely equipped, staffed or funded at the levels 
needed to conduct studies according to GLP and instead rely on independent replication to 
assess reliability and validity, which are not guaranteed using GLP. Regulatory agencies like the 
US EPA are bound by requirements that studies used in chemical risk assessments must be 
performed according to the GLP. This guidance was written to prevent the use of fraudulent 
studies conducted by contract laboratories and is now being used to exclude peer-reviewed, 
often government-funded studies conducted in academic laboratories from being used in risk 
assessment decision-making. This is especially concerning given the influence that funding 
source has been shown to have on study outcomes.17 29-31 
Further concerns are raised by the evaluations that have shown serious flaws in GLP- compliant 
studies including contamination of negative controls, lack of responsiveness to positive controls 
and technical problems including inadequate dissection techniques.31-33 Last, the rigorous 
reviews that are involved in obtaining grants from National Institutes of Health and other 
funding institutions before conducting research and the peer-review process that precedes 
publication of results are far more effective in identifying qualified, accurate science than is 
adhering to GLP.27 As illustrated in figure 2, all components of what would make science ‘sound’ 
but one is under the author’s control. Credit to and credibility of science rest on a single and 
crucial component: peer review. 
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A focus on scientific principles 
Scientific experts have argued that specific principles should be used in the evaluation of 
environmental chemicals with endocrine-disrupting properties.34 In particular, endocrinologists 
have noted that scientists studying EDCs must understand five principles of endocrinology: (1) 
the endocrine system coordinates the functions of the body from conception until death; (2) the 
effects of hormones are mediated via specific interactions with receptors; (3) hormones have 
different effects depending on life stage, with developmental exposures typically associated with 
permanent ‘organisational’ responses; (4) hormones act at low doses and (5) hormones can 
induce non-linear and non-monotonic dose responses. 
Considering these basic principles of hormones, a number of issues have been raised with the 
types of end points that are favoured in the evaluation of potential EDCs. The test guidelines 
developed in the 1930s are still in use (eg, OECD Test Guideline 440, the uterotrophic assay) for 
the evaluation of EDCs. The end points included in test guidelines use insensitive toxicity 
outcomes such as organ weight that do not reflect human disease processes.35 36 They also use a 
limited range of doses17 and rely on extrapolations to lower doses that are rarely tested for 
adverse effects. Furthermore, test guidelines assume the antiquated Paracelsian notion that the 
‘dose makes the poison’, rejecting or ignoring examples of non-monotonicity, even when they 
are present.37 Typical regulatory toxicology studies rarely justify the number of animals by 
power calculations, nor do they follow the rule to increase the number of animals as the tested 
dose decreases, as would be required to maintain power constant when the difference between 
exposed animals and controls is expected to decrease. The statistical tests used to identify 
‘thresholds’ are often rudimentary, if not statistically wrong. Finally, many test guidelines ignore 
critical periods in development, allowing some effects to be missed, producing misleading 
results and contributing to incorrect policy decisions. For example, an OECD guideline study 
suggests testing the effects of chemicals on female rodents at 22-42 days of life to evaluate the 
effects on puberty.38 Yet, it is well known that earlier periods including fetal and perinatal 
development are critical for maturing the signalling pathways that regulate the secretion of 
hormones at puberty as well as pubertal development of hormone-sensitive organs, as 
evidenced by the tragic history of the pharmaceutical diethylstilbestrol (DES). Young girls 
exposed to DES in utero developed cancers of the reproductive tract, and to date effects in so-
called DES sons and daughters are being elaborated, including obesity and additional cancers.39-
44 
A number of additional issues have been debated in the context of regulatory decisionmaking for 
EDCs. One debate surrounds the use of potency for the prioritisation, evaluation or even the 
identification of EDCs. Some arguments suggest that binding affinity can be used as a surrogate 
or predictor of the potency of a compound,45 46 so that chemicals with a low-binding affinity for a 
hormone receptor relative to the native hormone can be dismissed or ignored as ‘weak’ agonists 
(or antagonists).47 This notion is easily dismissed considering significant evidence that potency 
is end point-specific and, thus, cannot be predicted by the knowledge of binding affinity alone. 
For example, bisphenol A has been shown to be 10 000 or 100 000 times weaker than 17β-
oestradiol when considering its effects on uterine weight, but equipotent when considering its 
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effects on insulin release from pancreatic islets, and doses that have no effect on organ weight 
can alter the development of oestrogen-sensitive organs such as the brain.48-51 
Other issues related to the discussion of potency suggest that there are ‘adaptive’ responses 
after exposures to synthetic chemicals with low potency, and that these ‘weak’ EDCs do not 
cause obvious harm because the body is able to compensate for their effects.52 Yet evidence from 
pregnancy cohorts in humans demonstrates that so-called compensated or subclinical 
hypothyroidism contributes to adverse neurodevelopmental outcomes in children.53-55 Those 
groups that support the use of potency in the prioritisation of EDCs suggest that only those 
chemicals that cause overt and measurable toxic effects in animals such as tumour incidence 
should be restricted.46 This is an unscientific and dangerous distinction, analogous to the 
argument that has been made with regard to low-level lead exposures; industry consultants 
have repeatedly argued that effects on outcomes like IQ are not adverse.56 57 The social costs of 
IQ include lost lifetime economic productivity, intellectual disability and increased risk of 
criminality. Improved cognition and health from the phase-out of lead from gasoline, dismissed 
by some as irrelevant, produce $2.4 trillion in economic benefits globally each year, representing 
4% of global gross domestic product.58 
Similar to the arguments about potency, debate has surrounded issues related to ‘low-dose 
effects’ and the presence of thresholds (eg, doses below which no effects can be seen) for EDCs.15 
59 60 Again, conversations regarding these issues often address whether effects seen at low doses 
are representative of ‘adverse’ outcomes, and this discussion is further complicated by the 
inability or unwillingness of many regulatory agencies to describe which end points are 
adverse.19 34 61 62 
The cost of inaction 
Decisions about whether actions should be taken to protect public health often consider the 
financial implications of such actions, even when economic costs are not supposed to be 
considered in such evaluations. This has recently been raised in the European Union, where the 
European Commission was found to have broken the law in their delay to propose scientific 
criteria for the evaluation and identification of EDCs.24 Although draft criteria were proposed in 
2013, the European Commission has instead conducted an economic assessment of the various 
proposed draft criteria rather than use scientific principles, judgement and justification for the 
selection of final criteria. Economic assessments are also widely used in other countries (eg, by 
the Office of Information and Regulatory Affairs in the Office of Management and Budget in the 
USA). 
The problem with using economic assessments in environmental health decision-making is that 
typically only one side of the economic equation (eg, the cost to industry) is evaluated, leaving 
the costs of inaction (eg, environmental and health costs as well as reduced quality of life) 
unexamined. A historical example of this phenomenon comes from studies examining the 
association between air particulate and disease outcomes;63 estimates of the economic burden 
on industries including the fossil fuel industry suggested that the cost of reducing particulate 
matter would cripple the economy. Yet, additional evaluations showing the benefits to public 
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health of reducing particulate matter led to different conclusions: the economic benefits of 
improved health would outweigh the costs to industry.64 Recently, similar analyses were 
conducted which evaluated a limited number of EDC exposures for which there was the greatest 
evidence linking exposures to diseases and dysfunction. Six peer-reviewed articles were 
published in the Journal of Clinical Endocrinology and Metabolism attributing EDC exposures in 
Europe to healthcare costs of over €160 billion annually.11 12 65-68 These evaluations represent 
conservative estimates because they examined only 15 exposure-outcome relationships for 
which there is substantial probability for causation. In addition, because they did not include 
many indirect costs of chronic diseases due to EDCs and evaluated fewer than 5% of all EDCs, 
the cost estimates are likely to represent only a small subset of the true costs of EDCs in Europe. 
On the basis of the data from the US Centers for Disease Control and Prevention, a similarly large 
burden of disease may be attributable to EDCs in the USA; exposures to EDCs in the USA are in 
many cases equal to if not higher than those in the European Union. These findings speak to the 
substantial health and economic benefits that can be obtained by applying the best science, and 
not simply ‘sound science’, to inform regulatory policymaking. An additional issue is that the 
economic costs of regulation are often carried out in a simplistic way, assuming that the cost to 
the industry of banning a compound would correspond to the current market share of the 
compound. This amounts to assuming that if, for example, a pesticide is banned, the money 
formerly used to buy this pesticide will not be used to buy any other pesticide, nor anything else, 
and stored in a safe. 
Conclusions 
In the USA, the original 1976 Toxic Substances Control Act did not require that chemicals are 
tested prior to their use in many consumer products and industrial applications.69 Although the 
REACH (Registration, Evaluation, Authorization and Restriction of Chemicals) legislation and 
other regulations on pesticides and biocides in the European Union give the EU the authority to 
regulate these chemicals, additional debates about how EDCs should be defined and identified 
have prevented many anticipated chemical regulations and restrictions.70 
To date, the US Environmental Protection Agency has identified 10 517 chemicals for potential 
endocrine disruptor screening and testing, yet has only screened 52 chemicals with the tests in 
the Endocrine Disruptor Screening Programme (figure 1).71 72 In testing completed at the behest 
of the European Commission, 320 of 575 chemicals prioritised for screening showed evidence or 
potential evidence for endocrine disruption.73 These numbers illustrate the size of the problem, 
and the need for regulatory action. Moving forward, evaluations of EDCs should rely on scientific 
principles, well-designed and transparently reported studies and consideration of the economic 
costs of inaction. 
WHAT IS ALREADY KNOWN ON THIS SUBJECT 
Despite agreement by scientists and governments that chemicals contribute to disease by 
disrupting endocrine systems, ‘manufactured doubt’ continues to be cast as a cloud over 
rigorous, peer-reviewed and independently funded scientific data 
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WHAT THIS STUDY ADDS 
Moving forward, evaluations of endocrine disrupting chemicals should rely on scientific 
principles, well-designed and transparently reported studies and consideration of the economic 
costs of inaction 
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Figure 1. Identifying endocrine disruptor in the universe of synthetic chemicals 
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Figure 2. Components of peer-reviewed and unbiased science and stakeholders 
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